<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038063</url>
  </required_header>
  <id_info>
    <org_study_id>09.07</org_study_id>
    <nct_id>NCT01038063</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period</brief_title>
  <official_title>Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Malaria Control Programme, Malawi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research for Equity and Community Health Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Liverpool School of Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A community-based, open-label, cluster-randomised longitudinal study in which children are
      randomized according to village health worker catchment areas comparing the safety and
      effectiveness of repeated treatments with artemether-lumefantrine (AL) over a 3-year period
      in children 4-48 months to that of repeated treatment with dihydroartemisinin-piperaquine
      (DHA-PPQ).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of ototoxicity at 18 months and 36 months of enrolment.</measure>
    <time_frame>At 18 mo and 36 month of follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical malaria during 18 months and 36 months of follow-up</measure>
    <time_frame>18 and 36 months of follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Aged between 4 months and 11 months at the time of randomization

          2. Bodyweight â‰¥ 5 kg at the time of randomization

          3. Provision of informed consent by parent or guardian

          4. Intention to stay in the study area for the time of the study

        Exclusion criteria

          1. Ongoing participation into another clinical study involving ongoing or scheduled
             treatment with medicinal products

          2. Intent to reside outside of catchment area during the course of the study

          3. Known hypersensitivity to the study drug randomized to

          4. Known pre-existing hearing problem or neurological impairment

          5. Known need at the time of randomization for concomitant prohibited medication

          6. Suspected non-compliance with the follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lalloo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool School of Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Lalloo, MD</last_name>
    <phone>+44 151 705 3179</phone>
    <email>dlalloo@liverpool.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamija Phiri, MD PhD</last_name>
    <phone>+265 999 957 048</phone>
    <email>kamijaphiri@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Malawi-Liverpool-Wellcome Trust Research Programme, College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <zip>30096</zip>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamija Phiri, MD PhD</last_name>
      <phone>+265 999 957 048</phone>
      <email>kamijaphiri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kamija Phiri, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <link>
    <url>http://www.actconsortium.org</url>
    <description>The ACT Consortium is a global research partnership formed in November 2007 to answer key questions on malaria drug delivery in Africa and Asia.</description>
  </link>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sian Roberts / Head of Research Management</name_title>
    <organization>Liverpool School of Tropical Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

